GRADE-Leitlinien: 4. Bewertung der Qualität der Evidenz – Studienlimitationen (Risiko für Bias)
Authors:
- Joerg J. MeerpohlJMJoerg J. Meerpohl
- Gero LangerGLGero Langer
- Matthias PerlethMPMatthias Perleth
- Gerald GartlehnerGGGerald Gartlehner
- Angela Kaminski-HartenthalerAKAngela Kaminski-Hartenthaler
- Holger SchünemannHSHolger Schünemann
- 1 January 2012
- journal article
- Published by Elsevier in Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
- Vol. 106 (6) , 457-469
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Stopping Randomized Trials Early for Benefit and Estimation of Treatment EffectsSystematic Review and Meta-regression AnalysisJAMA, 2010
- Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label UseNew England Journal of Medicine, 2009
- Comparison of Registered and Published Primary Outcomes in Randomized Controlled TrialsJAMA, 2009
- Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological studyBMJ, 2008
- Randomized Trials Stopped Early for BenefitJAMA, 2005
- When (Not) to Stop a Clinical Trial for BenefitJAMA, 2005
- Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authorsBMJ, 2005
- Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health ResearchCanadian Medical Association Journal, 2004
- Empirical Evidence for Selective Reporting of Outcomes in Randomized TrialsJAMA, 2004
- Practical problems in interim analyses, with particular regard to estimationControlled Clinical Trials, 1989